Flolan
(Epoprostenol)ApprovedSmall molecule
Johnson & JohnsonFlolan is one of 128 small molecule programs targeting Ischemia. It is currently in Approved.
4
Indications
5
Total Trials
0
Active Trials
127
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
179 competitors in Pulmonary Arterial Hypertension
#DrugCompanyPhaseTrials
1Gleevec
NovartisPhase 3
Flolan
Johnson & JohnsonApproved
Reata
BiogenPhase 3
Levitra
BayerPhase 3
Aurlumyn
BBTG International Inc.
Phase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Atrovent
Boehringer IngelheimPhase 3
Inhaled Iloprost
BayerPhase 3
Frespaciguat
Merck & Co.Phase 3
Qutenza
AstellasPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ischemia1 trial
Pulmonary Hypertension1 trial
Regulatory
FDA Approval Timeline[4]
Sep 20, 1995
FLOLAN
NDA NDA020444
Jun 28, 2012
VELETRI
NDA NDA022260
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epoprostenol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Flolan. U.S. Food & Drug Administration.
- [6]